Reviews,  accounts and comments

Review, accounts and comments : 総説 

1. Tamanoi, F. (2023)「オージェ電子と放射線治療」, 放射線生物研究, 58, 1, 69-79.

2. Chinnathambi`, S. and Tamanoi, F. (2020) Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy. Pharmaceutics. 12, 890. doi: 10.3390/pharmaceutics12090890.

3. Tamanoi, F., Matsumoto, K., Doan, T.L.H., Shiro, A. and Saitoh, H. (2020)  Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy. Nanomaterials (Basel). 10, 1341. doi: 10.3390/nano10071341.

4. Komatsu, A., Matsumoto, K., Saito, T., Muto, M. and Tamanoi F. (2019)  Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Cells. 8, 440. doi: 10.3390/cells8050440. 

5. Hayashi, J.Y. and Tamanoi, F. (2017) Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. Enzymes.  42, 153-172. doi: 10.1016/bs.enz.2017.08.005. 

6. Bathaie, S.Z., Ashrafi, M., Azizian, M. and Tamanoi, F. (2017) Mevalonate Pathway and Human Cancers. Curr. Mol. Pharmacol. 10, 77-85. doi: 10.2174/1874467209666160112123205. 

7. Mekaru, H., Lu, J. and Tamanoi, F. (2015) Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Adv. Drug. Deliv. Rev. 95, 40-9. doi: 10.1016/j.addr.2015.09.009. 

8. Heard, J.J., Fong, V., Bathaie, S.Z. and Tamanoi, F. (2014) Recent progress in the study of the Rheb family GTPases. Cell Signal. 26, 1950-7. doi: 10.1016/j.cellsig.2014.05.011. 

9. Yanes, R.E. and Tamanoi, F. (2012) Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic Delivery 3, 389-404. doi: 10.4155/tde.12.9. 

10. Hardt, M., Chantaravisoot, N. and Tamanoi, F. (2011) Activating mutations of TOR (target of rapamycin). Genes Cells. 16, 141-51. doi: 10.1111/j.1365-2443.2010.01482.x. 

11. Sato, T., Nakashima, A. and Tamanoi, F. (2010) Rheb-mTOR signaling pathway involved in tumor formation. Tanpakushitsu Kakusan Koso. 55, 11-7. Japanese.

12. Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S.G., Nel, A.E., Tamanoi, F. and Zink, J.I. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS NANO 2, 889-896. doi: 10.1021/nn800072t. 

13. Aspuria, P.J., Sato, T. and Tamanoi, F. (2007) The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: Temperature sensitive and constitutive active mutants of TOR. Cell Cycle, 6, 1692-1695. doi: 10.4161/cc.6.14.4478. 

14. Gelb, M.H., Brunsveld, L., Hrycyna, C.A., Michaelis, S., Tamanoi, F., Van Voorhis, W.C. and Waldmann, H. (2006) Therapeutic intervention based on protein prenylation and associated modifications. Nature Chem. Biol. 10, 518-528. doi: 10.1038/nchembio818. 

15. Ikeda, A., Shankar, D.B., Watanabe, M., Tamanoi, F., Moore, T.B. and Sakamoto, K.M. (2006) Molecular targets and the treatment of myeloid leukemia. Mol. Genet. Metab. 88, 216-224. doi: 10.1016/j.ymgme.2006.03.011. 

16. Aspuria, P-J. and Tamanoi, F. (2004) The Rheb family of GTP-binding proteins. Cellular Signaling 16, 1105-1112. doi: 10.1016/j.cellsig.2004.03.019. 

17. Clarke, S. and Tamanoi, F. (2004) Fighting cancer by disrupting C-terminal methylation of signaling proteins. J. Clin. Invest. 113, 513-515. doi: 10.1172/JCI21059. 

18. Jiang, C., Kato-Stankiewicz, J., Gau, C.L. and Tamanoi, F. (2001) Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells. Gene Funct. Dis. 2, 2/3, 1-9.

19. Tamanoi, F., Kato-Stankiewicz, J., Jiang, C., Machado, I. and Thapar, N. (2001) Farnesylated proteins and cell cycle progression.  J. Cell. Biochem. 37, 6-70. doi: 10.1002/jcb.10067. 

20. Tamanoi, F., Gau, C.L., Edamatsu, H., Jiang, C. and Kato-Stankiewicz, J. (2001) Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell. Mol. Life Sci. 58, 1-14. doi: 10.1007/PL00000802. 

21. Urano, J. and Tamanoi, F. (1999) Reconstitution of yeast farnesyltransferase from individually purified subunits.  In Protein Lipidation Protocols, ed. M. Gelb, Humana Press, NJ, 145-159. doi: 10.1385/1-59259-264-3:145. 

22. Yang, W., Del Villar, K., Urano, J., Mitsuzawa, H. and Tamanoi, F. (1997) Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase.  J. Cellular Biochem, S27, 12-19.

23. Del Villar, K., Dorin, D., Sattler, I., Urano, J., Poullet, P., Robinson, N., Mitsuzawa, H. and Tamanoi, F. (1996)   C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochem Soc. Trans. 24, 709-713. doi: 10.1042/bst0240709. 

24. Tamanoi, F. (1993) Inhibitors of ras farnesyltransferases. TIBS, 18, 349-353. doi: 10.1016/0968-0004(93)90072-u. 

25. Tamanoi, F. (1988). Yeast RAS genes. Biochem. Biophys. Acta 948, 1-15. doi: 10.1016/0304-419x(88)90002-9.